Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for Tough-to-Treat myeloma: DREAMM 7 trial tests powerful combo

NCT ID NCT04246047

Ongoing Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new combination of drugs (belantamab mafodotin, bortezomib, and dexamethasone) against a standard combo (daratumumab, bortezomib, and dexamethasone) in 494 people whose multiple myeloma has come back or stopped responding to treatment. The goal is to see if the new combo can delay cancer growth longer. Participants must have had at least one prior therapy and have measurable disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

  • GSK Investigational Site

    Yuma, Arizona, 85364, United States

  • GSK Investigational Site

    Denver, Colorado, 80218, United States

  • GSK Investigational Site

    Kansas City, Kansas, 66205, United States

  • GSK Investigational Site

    Fairfield, Ohio, 45242, United States

  • GSK Investigational Site

    Tyler, Texas, 75702, United States

  • GSK Investigational Site

    Liverpool, New South Wales, 2170, Australia

  • GSK Investigational Site

    Wollongong, New South Wales, 2500, Australia

  • GSK Investigational Site

    Benowa, Queensland, 4217, Australia

  • GSK Investigational Site

    Brussels, 1090, Belgium

  • GSK Investigational Site

    Brussels, 1200, Belgium

  • GSK Investigational Site

    Ghent, 9000, Belgium

  • GSK Investigational Site

    Roeselare, 8800, Belgium

  • GSK Investigational Site

    Beijing, 100191, China

  • GSK Investigational Site

    Jinan, 250012, China

  • GSK Investigational Site

    Shenyang, 110001, China

  • GSK Investigational Site

    Alexandroupoli, 68 100, Greece

  • GSK Investigational Site

    Athens, 11528, Greece

  • GSK Investigational Site

    Thessaloniki, 54007, Greece

  • GSK Investigational Site

    Tel Aviv, 64239, Israel

  • GSK Investigational Site

    Bergamo, 24127, Italy

  • GSK Investigational Site

    Meldola FC, 47014, Italy

  • GSK Investigational Site

    Milan, 20133, Italy

  • GSK Investigational Site

    Siena, 53100, Italy

  • GSK Investigational Site

    Aichi, 441-8570, Japan

  • GSK Investigational Site

    Aichi, 467-8602, Japan

  • GSK Investigational Site

    Aomori, 030-8553, Japan

  • GSK Investigational Site

    Ehime, 790-8524, Japan

  • GSK Investigational Site

    Fukuoka, 806-8501, Japan

  • GSK Investigational Site

    Fukuoka, 807-8555, Japan

  • GSK Investigational Site

    Fukuoka, 810-8563, Japan

  • GSK Investigational Site

    Fukuoka, 815-8555, Japan

  • GSK Investigational Site

    Gifu, 503-8502, Japan

  • GSK Investigational Site

    Gunma, 377-0280, Japan

  • GSK Investigational Site

    Hyōgo, 670-8540, Japan

  • GSK Investigational Site

    Kanagawa, 221-0855, Japan

  • GSK Investigational Site

    Kanagawa, 247-8533, Japan

  • GSK Investigational Site

    Kochi, 781-8555, Japan

  • GSK Investigational Site

    Nagano, 392-8510, Japan

  • GSK Investigational Site

    Okayama, 701-1192, Japan

  • GSK Investigational Site

    Osaka, 530-0012, Japan

  • GSK Investigational Site

    Osaka, 545-8586, Japan

  • GSK Investigational Site

    Shizuoka, 411-8777, Japan

  • GSK Investigational Site

    Dordrecht, 3318 AT, Netherlands

  • GSK Investigational Site

    Groningen, 9713 GZ, Netherlands

  • GSK Investigational Site

    Chorzów, 41-500, Poland

  • GSK Investigational Site

    Krakow, 30510, Poland

  • GSK Investigational Site

    Lodz, 93-513, Poland

  • GSK Investigational Site

    Lublin, 20-081, Poland

  • GSK Investigational Site

    Lublin, 20-090, Poland

  • GSK Investigational Site

    Nowy Sącz, 33-300, Poland

  • GSK Investigational Site

    Poznan, 60-569, Poland

  • GSK Investigational Site

    Warsaw, 02-781, Poland

  • GSK Investigational Site

    Moscow, 125284, Russia

  • GSK Investigational Site

    Nizhny Novgorod, 603126, Russia

  • GSK Investigational Site

    Novosibirsk, 630087, Russia

  • GSK Investigational Site

    Saint Petersburg, 191024, Russia

  • GSK Investigational Site

    Saint Petersburg, 197 089, Russia

  • GSK Investigational Site

    Saratov, 410028, Russia

  • GSK Investigational Site

    Ufa, 450083, Russia

  • GSK Investigational Site

    Pusan, 49241, South Korea

  • GSK Investigational Site

    Ulsan, 44033, South Korea

  • GSK Investigational Site

    Barcelona, 08035, Spain

  • GSK Investigational Site

    Barcelona, 08916, Spain

  • GSK Investigational Site

    Cáceres, 10003, Spain

  • GSK Investigational Site

    Gijón, 33394, Spain

  • GSK Investigational Site

    L'Hospitalet de Llobrega, 08908, Spain

  • GSK Investigational Site

    Murcia, 30008, Spain

  • GSK Investigational Site

    PamplonaNavarra, 31008, Spain

  • GSK Investigational Site

    Salamanca, 37007, Spain